CHEK1 and diffuse large B-cell lymphoma: The dual CHK1/CHK2 inhibitor, PF-0477736 (Pfizer), is active in DLBCL cell lines and primary patient samples and also sensitizes TP53 mutant DLBCL cell lines to doxorubicin (89).